The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action

Rong Chen(Jiangsu University), William Plunkett(The University of Texas MD Anderson Cancer Center), Jennifer Tsai(Yale University), Jan A. Burger(The University of Texas MD Anderson Cancer Center), Philip A. Thompson(The Royal Melbourne Hospital), Mariela Sivina(The University of Texas MD Anderson Cancer Center), William G. Wierda(University of Maryland, Baltimore), Chaomei Liu(The University of Texas MD Anderson Cancer Center), Yuling Chen(The University of Texas MD Anderson Cancer Center), Francis Burrows(Fujikura (United States)), Ping Xiong(The University of Texas MD Anderson Cancer Center), Michael J. Keating(The University of Texas MD Anderson Cancer Center)
Blood Cancer Journal
March 13, 2021
10.1038/s41408-021-00436-0
Cited by 18

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k